



# The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017



GBD 2017 Pancreatic Cancer Collaborators\*

*Lancet Gastroenterol Hepatol*  
2019; 4: 934–47

Published Online  
October 21, 2019

[https://doi.org/10.1016/S2468-1253\(19\)30347-4](https://doi.org/10.1016/S2468-1253(19)30347-4)

See [Comment](#) page 895

\*Collaborators listed at the end of the paper

Correspondence to:  
Prof Mohsen Naghavi, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98121, USA  
[nagham@uw.edu](mailto:nagham@uw.edu)

or

Prof Reza Malekzadeh, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran  
[malek@tums.ac.ir](mailto:malek@tums.ac.ir)

## Summary

**Background** Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and more effective treatments.

**Methods** Vital registration, vital registration sample, and cancer registry data were used to generate mortality, incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework to estimate the proportion of deaths attributable to risk factors for pancreatic cancer: smoking, high fasting plasma glucose, and high body-mass index. All of the estimates were reported as counts and age-standardised rates per 100 000 person-years. 95% uncertainty intervals (UIs) were reported for all estimates.

**Findings** In 2017, there were 448 000 (95% UI 439 000–456 000) incident cases of pancreatic cancer globally, of which 232 000 (210 000–221 000; 51.9%) were in males. The age-standardised incidence rate was 5.0 (4.9–5.1) per 100 000 person-years in 1990 and increased to 5.7 (5.6–5.8) per 100 000 person-years in 2017. There was a 2.3 times increase in number of deaths for both sexes from 196 000 (193 000–200 000) in 1990 to 441 000 (433 000–449 000) in 2017. There was a 2.1 times increase in DALYs due to pancreatic cancer, increasing from 4.4 million (4.3–4.5) in 1990 to 9.1 million (8.9–9.3) in 2017. The age-standardised death rate of pancreatic cancer was highest in the high-income super-region across all years from 1990 to 2017. In 2017, the highest age-standardised death rates were observed in Greenland (17.4 [15.8–19.0] per 100 000 person-years) and Uruguay (12.1 [10.9–13.5] per 100 000 person-years). These countries also had the highest age-standardised death rates in 1990. Bangladesh (1.9 [1.5–2.3] per 100 000 person-years) had the lowest rate in 2017, and São Tomé and Príncipe (1.3 [1.1–1.5] per 100 000 person-years) had the lowest rate in 1990. The numbers of incident cases and deaths peaked at the ages of 65–69 years for males and at 75–79 years for females. Age-standardised pancreatic cancer deaths worldwide were primarily attributable to smoking (21.1% [18.8–23.7]), high fasting plasma glucose (8.9% [2.1–19.4]), and high body-mass index (6.2% [2.5–11.4]) in 2017.

**Interpretation** Globally, the number of deaths, incident cases, and DALYs caused by pancreatic cancer has more than doubled from 1990 to 2017. The increase in incidence of pancreatic cancer is likely to continue as the population ages. Prevention strategies should focus on modifiable risk factors. Development of screening programmes for early detection and more effective treatment strategies for pancreatic cancer are needed.

**Funding** Bill & Melinda Gates Foundation.

**Copyright** © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

## Introduction

Cancer incidence and mortality are rapidly increasing worldwide.<sup>1,2</sup> This increase is thought to be due to population growth and ageing, as well as changes in the prevalence of the main risk factors for cancer, several of which are associated with socioeconomic development.<sup>1,2</sup>

Pancreatic cancer remains one of the cancers with the poorest prognosis, with an overall 5-year survival rate of about 5%, without much difference between high-income countries and low-income and middle-income countries.<sup>3</sup> On the basis of the results of the previous

iteration of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), pancreatic cancer ranked eighth among cancers in mortality and 14th in incidence in 2016.<sup>1</sup> Pancreatic cancer incidence and mortality vary considerably in the world.<sup>1</sup> The highest incidence and mortality rates of pancreatic cancer are found in high-income countries.<sup>2</sup> Although the causes of pancreatic cancer are still insufficiently understood, certain risk factors have been identified, such as smoking, obesity, and diabetes.<sup>4</sup> These risk factors probably explain some of the national variation.

## Research in context

### Evidence before this study

Pancreatic cancer was estimated as the seventh leading cause of cancer death in both sexes worldwide in 2018, on the basis of the Global Cancer Incidence, Mortality and Prevalence 2018 estimates, from 185 countries, using subregional rather than national data. Because of the poor prognosis of pancreatic cancer, there were almost as many deaths ( $n=432\,000$ ) as there were cases ( $n=459\,000$ ). The rates reported were three times to four times higher in higher Human Development Index countries, with incidence rates being highest in Europe, North America, Australia, and New Zealand, and lowest in south central Asia. To our knowledge, there were no estimates of temporal patterns, trends, age patterns, years of life lost, disability-adjusted life-years, and associated risk factors of pancreatic cancer at national, regional, global, and socioeconomic levels before the Global Burden of Disease Study (GBD).

### Added value of this study

We present estimates of the global burden of pancreatic cancer based on results from GBD 2017, which are reported by sex and age groups for 195 countries and territories from 1990 to 2017. We also investigated the association of socioeconomic development status with incidence and mortality caused by

pancreatic cancer at the national level. We believe that this analysis provides the most comprehensive picture of the burden of pancreatic cancer to date. Examining trends of pancreatic cancer from 1990 to 2017 and comparisons across populations offers important information about the changing burden of pancreatic cancer to aid in the allocation of necessary resources at local levels to help control this lethal cancer.

### Implications of all the available evidence

The incidence and mortality rates of pancreatic cancer increased in almost all countries and territories from 1990 to 2017. With population growth and increases in longevity, clinicians and policy makers might expect a further substantial rise in the absolute number of pancreatic cancer cases, particularly in low-income and middle-income nations. Existing data gaps are a major challenge for policy making at the regional and national scale. To our knowledge, this study is the first effort to provide comprehensive worldwide estimates of the burden, epidemiological features, and risk factors of pancreatic cancer. Future studies should explore the predictors of these epidemiological trends to help policy makers implement cost-effective interventions for prevention, early detection, and control of pancreatic cancer.

Data about incidence and trends of pancreatic cancer and its risk factors are scarce, specifically in nuanced time and location dimensions. GBD is the first comprehensive and systematic effort to report the incidence of and mortality and disability caused by pancreatic cancer and its risk factors, using an extensive set of data sources and novel statistical methods in seven super-regions, 21 regions, and 195 countries and territories, for both sexes and 20 age groups, from 1990 to 2017. To our knowledge, this study is the first to investigate the association between development status (measured by the Socio-demographic Index [SDI]) and pancreatic cancer incidence and mortality at the national level.

## Methods

### Overview

This study is part of GBD. In the latest iteration, GBD 2017, 359 diseases and injuries, 282 causes of death, and 84 risk factors were estimated. The rationale, methods, and summary results of GBD 2017 have been published previously.<sup>5–8</sup> Rates and numbers of deaths, incident cases, years of life lost (YLLs) as a result of premature death, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were reported for both males and females, 17 age groups, and 195 countries and territories.

The rates were age-standardised according to the world population estimated by the GBD study.<sup>9</sup> 95% uncertainty intervals (UIs) were reported for all estimates, including all sources of uncertainty arising from measurement error, systematic biases, and modelling. This study is

compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).

### Data sources

We considered all cancers coded as C25–C25.9 in the 10th revision of the International Classification of Diseases to be pancreatic cancer and mapped them to the GBD cause list.<sup>5,7</sup> For this study, we used GBD 2017 vital registration and sample vital registration (19 321 site-years of data) and cancer registry (4472 site-years) data.<sup>7</sup> Vital registration systems include vital event data from all residents in a population, including causes of death. Sample vital registration systems include nationally representative data from which birth rates, death rates, and causes of death can be estimated. Cancer registries include data on all cancer patients in a defined population, typically from a particular location. Detailed information on data sources used in this study can be found on the GBD 2017 Data Input Sources Tool website.

### Mortality estimates

Data coverage and quality were higher for mortality data than for other measures of pancreatic cancer burden. The cancer registry mortality estimates that were uploaded into the causes of death database were derived from cancer registry incidence data that had been transformed to mortality estimates through the use of mortality-to-incidence ratios (MIRs). We modelled MIRs using the locations that had both incidence and mortality data for the same year. The initial MIR model used a linear-step mixed-effects

For the GBD 2017 Data Input Sources Tool see <http://ghdx.healthdata.org/gbd-2017/data-input-sources>

model with logit link functions. The resulting estimates were then smoothed over place and time, and adjusted using spatiotemporal Gaussian process regression (see appendix of reference 10).<sup>10</sup> The vital registration mortality, as well as the cancer registry mortality estimates computed from MIRs, were used as inputs for a Cause of Death Ensemble model.<sup>7,11</sup>

### Non-fatal estimates

Pancreatic cancer incidence was computed by dividing the final mortality estimates by the MIR. Four sequelae were defined for pancreatic cancer—diagnosis and primary therapy phase, controlled phase, metastatic phase, and terminal phase.<sup>1</sup> The diagnosis and primary therapy phase was defined as 4.1 months, the disseminated and metastatic phase as 2.54 months, and terminal phase as 1.0 month.<sup>12,13</sup> The remaining time was assigned to the controlled phase. Following this process, to estimate the sequela-specific YLDs, we multiplied each sequela-specific prevalence rate by a sequela-specific disability weight. Each of the four sequelae had defined disability weights that ranged from 0.049 to 0.540 (appendix p 8). DALYs were calculated as the sum of YLDs and YLLs.

See Online for appendix

### SDI

We used the SDI to determine the relationship between pancreatic cancer incidence and mortality rates with development status at national and regional levels. The SDI ranges from 0 (worst) to 1 (best) and is composed of the total fertility rate among women under the age of 25 years, mean education for individuals aged 15 years and older, and lag-distributed income per capita.<sup>5-7</sup> Components were extracted using principal components analysis. Each component was given equal weight, and the final SDI score was computed as the geometric mean of each of the components.

### Risk factors

We used the comparative risk assessment framework to estimate the proportion of deaths and DALYs attributable to three recognised risk factors for pancreatic cancer: smoking, high fasting plasma glucose, and high body-mass index (BMI). We used the counterfactual scenario of theoretical minimum risk exposure level to model the population attributable fraction. The definitions of the framework have already been published.<sup>8</sup>

### Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and the final responsibility for the decision to submit for publication.

### Results

The number of incident cases of pancreatic cancer in both sexes increased 2.3 times from 195 000 (95% UI


192 000–199 000) incident cases in 1990 to 448 000 (439 000–456 000) cases in 2017 globally (appendix p 19). In 2017, 51.9% (232 000 [210 000–221 000]) of the total incident cases occurred in males, compared with 52.1% (102 000 [99 000–106 000]) in 1990.

The global age-standardised incidence rate was 5.0 (95% UI 4.9–5.1) per 100 000 person-years in 1990, which increased to 5.7 (5.6–5.8) per 100 000 person-years in 2017 (appendix p 19). Globally, there were 9.1 million (8.9–9.3) DALYs due to pancreatic cancer in 2017. This was a 2.1 times increase from 4.4 million (4.3–4.5) DALYs in 1990 (appendix p 27). 99% of all DALYs in all years were due to YLLs (appendix p 7).

In 2017, pancreatic cancer caused 441 000 (95% UI 433 000–449 000) deaths globally, including 226 000 (51.3%; 219 000–233 000) deaths among males and 215 000 (48.7%; 211 000–220 000) deaths among females. There was a 2.3 times (125% [118–131]) increase in the number of deaths globally from 1990 to 2017, increasing from 196 000 (193 000–200 000) deaths for both sexes combined in 1990. The age-standardised death rate increased by 10.4% (7.0–13.0), from 5.1 (5.0–5.2) per 100 000 person-years in 1990 to 5.6 (5.5–5.7) per 100 000 person-years in 2017 (appendix p 11). The age-standardised death rate in males was 5.7 (5.6–5.9) per 100 000 person-years in 1990 and 6.3 (6.1–6.5) per 100 000 person-years in 2017. The equivalent findings for females were 4.5 (4.5–4.6) per 100 000 person-years in 1990 and 5.0 (4.9–5.1) per 100 000 person-years in 2017.

The age-standardised death rate was highest in the high-income super-region across all years from 1990 to 2017: 8.1 (8.1–8.2) per 100 000 person-years in 1990 and 8.6 (8.5–8.8) per 100 000 person-years in 2017 (appendix p 2). Central Europe, eastern Europe, and central Asia ranked second at 6.8 (6.5–7.0) per 100 000 person-years in 1990 and 7.6 (7.5–7.8) per 100 000 person-years in 2017. South Asia had the lowest rates: 1.6 (1.4–1.8) per 100 000 person-years in 1990 and 2.9 (2.7–3.0) per 100 000 person-years in 2017. The pattern of age-standardised incidence rates in super-regions was similar to the pattern we observed for age-standardised death rate (appendix p 2). The pattern of age-standardised incidence and death rates was also similar between sexes (data not shown).

Age-standardised incidence and death rates increased in all GBD regions from 1990 to 2017 (figure 1). High-income North America and western Europe were among the top three regions for highest age-standardised rates of both incidence and deaths in 2017, with high-income Asia Pacific and central Europe also in the top three for highest age-standardised rate of incidence and death, respectively (figure 1). These regions all had smaller increases in age-standardised rates of incidence and deaths from 1990 to 2017 than many other regions (figure 1B, D; appendix pp 11–26). The lowest age-standardised incidence and death rates in 2017 were observed in south Asia and eastern and central



**Figure 1: Levels and trends in age-standardised incidence and death rates of pancreatic cancer across 21 GBD regions by sex**


(A) The age-standardised incidence rates of pancreatic cancer in 2017. (B) The percentage change in age-standardised incidence rate of pancreatic cancer from 1990 to 2017. (C) The age-standardised death rates of pancreatic cancer in 2017. (D) The percentage change in age-standardised death rate of pancreatic cancer from 1990 to 2017. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.

sub-Saharan Africa (figure 1A, C). The Caribbean, Andean Latin America, and central Asia had the highest percentage change in both incidence and death rates from 1990 to 2017 (figure 1B, D). The age-standardised rates for both incidence and death were higher among males than females in almost all regions and all years from 1990 to 2017, with the exception of Andean Latin America and western sub-Saharan Africa (figure 1A, C).

Age-specific rates for both incidence and deaths increased with increasing age; this trend was similar between males and females (figure 2A, B). The number of both deaths and incident cases peaked at the ages of 65–69 years in males, whereas the peak in females was observed at the ages of 75–79 years. Additionally, the numbers of deaths and incident cases were lower in females younger than 75 years than in males in the same age group, whereas the numbers were higher in females

than in males in age groups of 75 years and older (figure 2A, B). Until the ages of 90–94 years, the incidence, death, and DALYs rates were higher in males than in females in the same age group (figure 2). The age pattern for number of DALYs showed a similar trend to number of deaths and incident cases for total counts, but the rates decreased in age groups older than 80 years. Similar to the number of incident cases and deaths, in 2017 the number of DALYs was much higher in males than in females in all age groups younger 75 years, after which female DALY numbers were higher (although with overlapping uncertainty in the age group of 75–79 years).

In both 1990 and 2017, the highest age-standardised death rates were observed in Greenland: 19.7 (95% UI 17.8–21.8) per 100 000 person-years in 1990 and 17.4 (15.8–19.0) per 100 000 person-years in 2017 (figure 3A; appendix p 11). Yet the number of deaths due to pancreatic



**Figure 2:** Age-specific counts and rates of incident cases (A), deaths (B), and DALYs (C) of pancreatic cancer by sex, 2017  
 DALYs=disability-adjusted life-years.

cancer in Greenland was among the lowest in the world (11.1 [10.2–12.1] in 2017). Uruguay was the next leading country for highest age-standardised death rates from pancreatic cancer, although it was substantially behind Greenland, with an age-standardised death rate of 12.1 (10.9–13.5) per 100 000 person-years in 2017. Bangladesh (1.9 [1.5–2.3] per 100 000 person-years) had the lowest age-standardised rate in 2017, whereas São Tomé and Príncipe (1.3 [1.1–1.5] per 100 000 person-years) had the

lowest rate in 1990. The incidence rates followed a very similar pattern: highest in Greenland in both 1990 and 2017, lowest in São Tomé and Príncipe in 1990, and lowest in Bangladesh in 2017 (figure 3B). All estimates were similar between males and females (data not shown). Specific country and territory data for incidence, deaths, and DALYs can be found in the appendix (pp 11–34).

The average annualised percentage change in both age-standardised incidence and death rates was highest in Grenada (5.5%) and lowest in Bahrain (–1.2%) from 1990 to 2017. For males, the percentage change in both age-standardised incidence and death rates was highest in Bermuda (6.0%) and lowest in Qatar (–1.5% for age-standardised incidence rate and –1.6% for age-standardised death rate). For females, the highest percentage change in both age-standardised incidence and death rates was in Grenada (5.4% for age-standardised incidence rate and 5.5% for age-standardised death rate) and the lowest in Bahrain (–1.2%).

93 600 (95% UI 82 500–108 000) pancreatic cancer deaths, equivalent to 21.1% (18.8–23.7) of all age-standardised deaths from pancreatic cancer, were attributable to smoking for both sexes combined in 2017. The age-standardised proportions of all pancreatic cancer deaths that were attributable to smoking in 2017 were 25.9% (22.2–29.6) for males and 16.1% (13.2–18.8) for females (figure 4A). 59 000 (63.1%; 50 000–68 000) of these deaths occurred in males and 33 500 (36.1%; 28 000–41 000) in females. In 1990, the proportion of pancreatic cancer age-standardised deaths attributable to smoking was 26.6% (23.8–29.5) for both sexes combined.

Globally, in 2017, 8.9% (2.1–19.4) of pancreatic cancer age-standardised deaths were attributable to high fasting plasma glucose, including 9.3% (1.7–21.3) in males and 8.6% (1.4–19.6) in females (figure 4A; appendix pp 8–9), compared with 7.7% (1.8–16.8) for both sexes combined in 1990. Likewise, 6.2% (2.5–11.4) of pancreatic cancer age-standardised deaths were attributable to high BMI, including 5.0% (0.0–12.1) in males and 7.4% (2.6–13.0) in females (figure 4A; appendix pp 8–9), compared with 5.0% (1.9–9.6) for both sexes combined in 1990.

In 2017, the proportion of age-standardised deaths attributable to smoking for males was highest in eastern Europe (35.7% of all pancreatic cancer deaths) and east Asia (31.3%); for females it was highest in high-income North America (29.3%) and southern Latin America (27.6%). The lowest age-standardised attributable proportion for smoking was observed in western sub-Saharan Africa for both males (8.0%) and females (2.1%). In 2017, the highest proportion of age-standardised deaths attributable to high fasting plasma glucose was observed in Oceania in both males (16.0%) and females (17.3%), and the highest fraction attributable to high BMI was observed in high-income North America for both males (8.6%) and females (11.7%). Additionally, in 2017, the lowest proportion of age-standardised deaths




Figure 3: Age-standardised rates of incidence (A) and death (B) of pancreatic cancer across 195 countries and territories in both sexes, 2017





Figure 4: Fraction of pancreatic cancer age-standardised deaths attributable to smoking, high fasting plasma glucose, and high body-mass index by region (A) and fraction of pancreatic cancer age-specific deaths attributable to smoking, high fasting plasma glucose, and high body-mass index by age group (B) for males and females, 2017

attributable to high fasting plasma glucose was observed in east Asia in males (5.8%) and in tropical Latin America in females (6.1%). As for proportion of deaths attributable to high BMI, the lowest proportion in males was observed in eastern sub-Saharan Africa (2.1%), and in females the lowest proportion was observed in high-income Asia Pacific (3.5%; figure 4A).

Across age groups, the proportion of age-standardised deaths attributable to smoking was higher than 25% in males aged between 55 and 84 years and higher than 16% in females in the same age group (figure 4B). The highest proportion attributable to high fasting plasma glucose in both sexes was observed in the 85–89 year

age group. Although higher proportions of pancreatic cancer deaths attributable to high BMI were observed between the ages of 45 years and 79 years, the proportions were more similar between all age groups than for the leading risk factors, with attributable deaths starting to occur at the ages of 20–24 years (figure 4B).

From 1990 to 2017, the age-standardised rates of both deaths and incidence of pancreatic cancer increased, along with increases in SDI. That is, the lowest rates were observed in low SDI countries and higher rates were detected in countries with respectively higher SDI across all years from 1990 to 2017 (appendix p 3).



**Figure 5: The trend in age-standardised death rates of pancreatic cancer across 21 GBD regions by SDI for both sexes combined, 1990–2017**

For each region, points from left to right depict estimates from each year from 1990 to 2017. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.

Figure 5 demonstrates the trend in age-standardised death rates across SDI by region, from 1990 to 2017. Regions generally followed the trend of increasing death, incidence, and DALY rates along with increases in SDI (figure 5; appendix pp 4–5). Several regions, including Andean Latin America and southern sub-Saharan Africa, showed a decrease in age-standardised death rate late in the study period, but not down to 1990 levels. Among high-income regions, Australasia had a rising age-standardised death rate but it was well below the expected levels in all years, while other high-income regions were either near or above the levels expected on the basis of SDI. Although south Asia, southeast Asia, and east Asia had rising age-standardised death rates, they were among the lowest in the world and were below the expected levels in all years from 1990 to 2017. Figure 6 demonstrates the association between age-standardised death rate and SDI across countries and territories in 2017. Similar to regional trends, there was a trend at the national level of increasing age-standardised death rates along with increases in SDI. As mentioned previously, the observed levels were much higher than expected in Greenland and Uruguay and much lower than expected in many countries, including Bangladesh, Kuwait, and Singapore based solely on SDI.

## Discussion

Our results showed that there were approximately 441 000 deaths due to pancreatic cancer worldwide in 2017. The incidence and death rates of pancreatic cancer for both sexes varied greatly across GBD regions. The 2017 age-standardised death rates for pancreatic cancer were highest in Greenland and Uruguay. The lowest were

observed in Bangladesh and São Tomé and Príncipe. Although there was not a clear explanation for such great differences in pancreatic cancer mortality in different regions of the world, this national variation could be attributed to exposure to known or suspected lifestyle and environmental risk factors related to pancreatic cancer as well as scarcity of efficient diagnostic tools in low-income and middle-income countries.<sup>14,15</sup> The substantial increase in worldwide pancreatic cancer suggests that change in ageing populations, especially in low and middle SDI countries, and environmental and behavioural changes, more so than genetic factors, are related to its cause. Differences in pancreatic cancer death and incidence rates across countries could also reflect variation in quality of cancer registry data and tools for pancreatic cancer diagnosis.<sup>16,17</sup>

Since 1990, regional age-standardised death and incidence rates of pancreatic cancer generally increased with increasing SDI. During the past three decades, these rates were consistently higher in high SDI regions and lower in low SDI regions. Higher incidence of pancreatic cancer in high SDI countries could be due to the ageing population and to lifestyle choices that increase exposure to risk factors; some of the risk factors for pancreatic cancer are more prevalent in high SDI countries than in low ones.<sup>2,18</sup>

There was a 2–3 times increase in global number of incident cases and deaths of pancreatic cancer in both sexes from 1990 to 2017, reflecting both ageing and growth of the population, especially in low and middle SDI countries. The age-standardised death and incidence rates increased from 1990 to 2017 at the global level. This





females between 1990 and 2015; however, four countries had significant annualised increases in smoking prevalence between 2005 and 2015 (Congo and Azerbaijan for males and Kuwait and Timor-Leste for females).<sup>21</sup> On the basis of a 2012 study<sup>28</sup> by the International Pancreatic Cancer Case-Control Consortium (PanC4; 6507 pancreatic cancer cases, 12890 controls), former smokers, in comparison with never smokers, had an odds ratio (OR) of 1.2 (95% CI 1.0–1.3), and current smokers, in comparison with never smokers, had an OR of 2.2 (1.7–2.8), for risk of pancreatic cancer, with a trend of significantly increasing risk of pancreatic cancer with increasing number of cigarettes among current smokers (OR 3.4 for  $\geq 35$  cigarettes per day,  $p_{\text{trend}} < 0.0001$ ). Risk increased in relation to duration of cigarette smoking up to 40 years of smoking (OR 2.4).<sup>28</sup> No trend in risk was observed for age at starting cigarette smoking, whereas risk decreased with increasing time since cigarette cessation, with an OR of 0.98 after 20 years.<sup>28</sup> We found that the highest proportion of pancreatic cancer deaths attributable to smoking for both sexes was observed in the 55–84 year age group, which is consistent with the findings from the PanC4.<sup>28</sup> The International Agency for Research on Cancer confirmed that smoking is causally associated with pancreatic cancer.<sup>29</sup>

Type 2 diabetes has been linked with an excess risk of pancreatic cancer in several studies.<sup>30–32</sup> We found that 8.8% of pancreatic cancer deaths were attributable to high fasting plasma glucose in both sexes in 2017. By comparison, a population study in Italy estimated that 9.7% of pancreatic cancer occurrence was attributable to diabetes.<sup>33</sup> The US National Cancer Institute estimated that diabetes is associated with a 1.8 times increased risk of pancreatic cancer.<sup>34</sup> From 1980 to 2014, in all countries, diabetes prevalence in adults either increased, especially in low and middle SDI locations, or at best remained unchanged; worldwide, the number of adults with diabetes has quadrupled,<sup>19</sup> so it is expected that diabetes will have a greater contribution to pancreatic cancer occurrence in the future.

Large studies have indicated a positive association between increasing BMI and risk of pancreatic cancer.<sup>18,35</sup> A pooled study<sup>35</sup> of seven prospective cohorts showed that compared with normal weight (BMI 18.5 to <25), the adjusted relative risk for pancreatic cancer was 1.13 for overweight (BMI 25 to <30 kg/m<sup>2</sup>) and 1.19 for obesity class I (BMI 30 to <35 kg/m<sup>2</sup>). A pooled analysis from the Pancreatic Cancer Cohort Consortium<sup>18</sup> showed that in males, the adjusted OR for pancreatic cancer for the highest versus lowest quartile of BMI was 1.33, and in females it was 1.34. The prevalence of obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) is increasing at an alarming rate in many parts of the world. The number of obese people has risen globally from 105 million in 1975 to 641 million in 2014. Since 1975, the prevalence of obese males has more than tripled, and that of obese females has more than doubled.<sup>36</sup> More than 2 billion people are

overweight, and a third of them are obese. By 2025, global obesity prevalence is projected to reach 18% in males and surpass 21% in females; severe obesity is likely to surpass 6% in males and 9% in females.<sup>19</sup> We found that 6.2% of pancreatic cancer in both sexes (5.0% in males, 7.4% in females) was attributable to obesity, which is inconsistent with estimated population attributable fractions (3–16%).<sup>27</sup> Although obesity carries a modest risk for pancreatic cancer, its rapid increase makes it a serious risk factor for pancreatic cancer, especially in females, who are more commonly obese than males.

Future strategies should include comprehensive policies to control tobacco use and reduce the burden of obesity and diabetes across the world. Additionally, efforts must be made to identify other modifiable risk factors for pancreatic cancer, such as opium use in North Africa and the Middle East.<sup>37,38</sup>

This study has several limitations. Generally, as for estimation of all diseases and cancers in the GBD study, the major limitation of the current study is the lack of high-quality data in many regions and countries, particularly in low-income locations. Although we did a sensitive search to take advantage of all available data sources comprising cancer registries and vital registration systems, in many locations data were either sparse or entirely unavailable. For estimating pancreatic cancer burden in these locations, we had to base our estimations on covariates and spatiotemporal smoothing. Ascertainment bias, detection bias, and diagnostic inaccuracy were additional limitations in low-income locations. The reported high incidence and mortality of pancreatic cancer in high-income versus low-income locations might be partly related to availability of accurate diagnostic modalities for pancreatic cancer and richness of data in high-income regions. Additionally, all of the general limitations in estimating the burden attributable to risk factors through comparative risk assessment methods were challenging. Finally, because of lags in data availability, recent estimates of trends relied on covariates and past trends, leading to wider UIs.

Pancreatic cancer deaths and incidence more than doubled over the study period. Much of this increase was due to increases in population and longevity, but even after accounting for population changes, incidence and death rates increased from 1990 to 2017, probably due to changes in associated risk factors. Pancreatic cancer is an aggressive cancer, predicted to become the second leading cause of cancer deaths in some regions. It often presents in old age, at an advanced stage, and has a poor prognosis. Major risk factors associated with pancreatic cancer (smoking, diabetes, and obesity) are potentially modifiable, affording a unique opportunity for preventing one of the deadliest cancers. The results of our study can be used by policy makers to allocate resources efficiently for developing methods for early diagnosis of pancreatic cancer, reducing its modifiable risk factors, and

evaluating novel treatment strategies to reduce its case-fatality rate by proper treatment strategies.

#### GBD 2017 Pancreatic Cancer Collaborators

Akram Pourshams, Sadaf G Sepanlou, Kevin S Ikuta, Catherine Bisignano, Saeid Safiri, Gholamreza Roshandel, Mehdi Sharif, Morteza Khatibian, Christina Fitzmaurice, Molly R Nixon, Nooshin Abbasi, Mohsen Afarideh, Elham Ahmadian, Tomi Akinyemiju, Fares Alahdab, Tahiya Alam, Vahid Alipour, Christine A Allen, Nahla Hamed Anber, Alireza Ansari-Moghaddam, Jalal Arabloo, Alaa Badawi, Mojtaba Bagherzadeh, Yaschilal Muche Belayneh, Belete Biadgo, Ali Bijani, Antonio Biondi, Tone Bjørge, Antonio M Borzi, Cristina Bosetti, Andrey Nikolaevich Briko, Nikolay Ivanovich Briko, Giulia Carreras, Félix Carvalho, Jee-Young J Choi, Dinh-Toi Chu, Anh Kim Dang, Ahmad Daryani, Dragos Virgil Davitoui, Gebre Teklemariam Demoz, Rupak Desai, Subhjit Dey, Hoa Thi Do, Huyen Phuc Do, Aziz Eftekhari, Alireza Esteghamati, Farshad Farzadfar, Eduarda Fernandes, Irina Filip, Florian Fischer, Masoud Foroutan, Mohamed M Gad, Silvano Gallus, Birhanu Geta, Giuseppe Gorini, Nima Hafezi-Nejad, James D Harvey, Milad Hasankhani, Amir Hasanzadeh, Soheil Hassanipour, Simon I Hay, Hagos D Hidru, Chi Linh Hoang, Sorin Hostiuc, Mowafa Househ, Olayinka Stephen Ilesanmi, Milena D Ilic, Seyed Sina Naghibi Irvani, Nader Jafari Balalami, Spencer L James, Farahnaz Joukar, Amir Kasaieian, Tesfaye Dessale Kassa, Andre Pascal Kengne, Rovshan Khalilov, Ejaz Ahmad Khan, Amir Khater, Fatemeh Khosravi Shadmani, Jonathan M Kocarnik, Hamidreza Komaki, Ai Koyanagi, Vivek Kumar, Carlo La Vecchia, Platon D Lopukhov, Farzad Manafi, Navid Manafi, Ana-Laura Manda, Fariborz Mansour-Ghanaei, Dhruv Mehta, Varshil Mehta, Toni Meier, Hagazi Gebre Meles, Getnet Mengistu, Tomasz Miazgowski, Mehdi Mohammadnejad, Abdollah Mohammadian-Hafshejani, Milad Mohammadoo-Khorasani, Shafiu Mohammed, Farnam Mohebi, Ali H Mokdad, Lorenzo Moosta, Maryam Moossavi, Rahmatollah Moradzadeh, Gurudatta Naik, Ionut Negoii, Cuong Tat Nguyen, Long Hoang Nguyen, Trang Huyen Nguyen, Andrew T Olagunju, Tinuke O Olagunju, Alyssa Pennini, Mohammad Rabiee, Navid Rabiee, Amir Radfar, Mahdi Rahimi, Goura Kishor Rath, David Laith Rawaf, Salman Rawaf, Robert C Reiner Jr, Nima Rezaei, Aziz Rezapour, Anas M Saad, Seyedmohammad Saadatagah, Amirhossein Sahebkar, Hamideh Salimzadeh, Abdallah M Samy, Juan Sanabria, Arash Sarvezaad, Monika Sawhney, Mario Sekerija, Pavel Shabalkin, Masood Ali Shaikh, Rajesh Sharma, Sara Sheikhbahaei, Reza Shirkoohi, Sudeep K Siddappa Malleshappa, Mekonnen Sisay, Kjetil Soreide, Sergey Soshnikov, Rasoul Sotoudehmanesh, Vladimir I Starodubov, Michelle L Subart, Rafael Tabarés-Seisdedos, Degena Bahray Bahrey Tadesse, Eugenio Traini, Bach Xuan Tran, Khanh Bao Tran, Irfan Ullah, Marco Vacante, Amir Vahedian-Azimi, Elena Varavikova, Ronny Westerman, Dawit Zewdu Wondafrash, Rixing Xu, Naohiro Yonemoto, Vesna Zadnik, Zhi-Jiang Zhang, Reza Malekzadeh\*, and Mohsen Naghavi\*. \*These authors jointly supervised the study.

#### Affiliations

Digestive Diseases Research Institute (Prof A Pourshams MD, S G Sepanlou MD, G Roshandel PhD, M Khatibian MD, M Mohammadnejad MD, H Salimzadeh PhD, Prof R Sotoudehmanesh BHLthSci, Prof R Malekzadeh MD), Cancer Biology Research Center (R Shirkoohi PhD), Cancer Research Institute (R Shirkoohi PhD), Department of Cardiology (S Saadatagah MD), Department of Microbiology (A Hasanzadeh PhD), Endocrinology and Metabolism Research Center (M Afarideh MD, Prof A Esteghamati MD, S Sheikhbahaei MD), Hematologic Malignancies Research Center (A Kasaieian PhD), Hematology-Oncology and Stem Cell Transplantation Research Center (A Kasaieian PhD), Iran National Institute of Health Research (F Mohebi MD), Liver and Pancreatobiliary Diseases Research Center (M Mohammadnejad MD), Non-communicable Diseases Research Center (F Farzadfar MD, F Mohebi MD), Research Center for Immunodeficiencies (Prof N Rezaei PhD), School of Medicine (N Hafezi-Nejad MD), Tehran University of Medical Sciences, Tehran, Iran; Non-communicable Diseases Research Center (S G Sepanlou MD,

Prof R Malekzadeh MD), Shiraz University of Medical Sciences, Shiraz, Iran; Institute for Health Metrics and Evaluation (K S Ikuta MD, C Bisignano MPH, C Fitzmaurice MD, M R Nixon PhD, T Alam MPH, C A Allen BA, J D Harvey BS, Prof S I Hay FMedSci, S L James MD, J M Kocarnik PhD, Prof A H Mokdad PhD, A Pennini MSc, R C Reiner Jr PhD, M L Subart BA, M L Subart BA, R Xu BS, Prof M Naghavi MD), Division of Allergy and Infectious Diseases (K S Ikuta MD), Division of Hematology (C Fitzmaurice MD), Department of Health Metrics Sciences, School of Medicine (Prof S I Hay FMedSci, Prof A H Mokdad PhD, R C Reiner Jr PhD, Prof M Naghavi MD), University of Washington, Seattle, WA, USA; Aging Research Institute (S Safiri PhD), Department of Community Medicine (S Safiri PhD), Department of Pharmacology and Toxicology (E Ahmadian PhD, A Eftekhari PhD), Drug Applied Research Center (M Rahimi PhD), School of Nutrition and Food Sciences (M Hasankhani MSc), Tabriz University of Medical Sciences, Tabriz, Iran; Golestan Research Center of Gastroenterology and Hepatology (G Roshandel PhD), Golestan University of Medical Sciences, Gorgan, Iran; Department of Basic Sciences (Prof M Sharif PhD), Department of Laboratory Sciences (Prof M Sharif PhD), Islamic Azad University, Sari, Iran; Montreal Neurological Institute (N Abbasi MD), McGill University, Montreal, QC, Canada; Department of Physiology (R Khalilov PhD), Institute of Radiation Problems of Azerbaijan, Baku State University, Baku, Azerbaijan (E Ahmadian PhD); Department of Population Health Sciences (T Akinyemiju PhD), Duke Global Health Institute (T Akinyemiju PhD), Duke University, Durham, NC, USA; Evidence-Based Practice Center (F Alahdab MD), Mayo Clinic Foundation for Medical Education and Research, Rochester, MN, USA; Colorectal Research Center (A Sarvezaad PhD), Health Economics Research Center (V Alipour PhD, J Arabloo PhD, A Rezapour PhD), Ophthalmology Department (N Manafi MD), Iran University of Medical Sciences, Tehran, Iran; Faculty of Medicine (N H Anber PhD), Mansoura University, Mansoura, Egypt (N H Anber PhD); Department of Epidemiology and Biostatistics (Prof A Ansari-Moghaddam PhD), Health Promotion Research Center, Zahedan, Iran; Public Health Risk Sciences Division (A Badawi PhD), Public Health Agency of Canada, Toronto, ON, Canada; Department of Nutritional Sciences (A Badawi PhD), Joint Centre for Bioethics (F Manafi MD), University of Toronto, Toronto, ON, Canada; Department of Chemistry (Prof M Bagherzadeh PhD, N Rabiee PhD), Sharif University of Technology, Tehran, Iran; Department of Pharmacy (Y M Belayneh MSc, B Geta MSc, G Mengistu MSc), Wollo University, Dessie, Ethiopia; Department of Clinical Chemistry (B Biadgo MSc), University of Gondar, Gondar, Ethiopia; Social Determinants of Health Research Center (A Bijani PhD), Babol University of Medical Sciences, Babol, Iran; Department of Clinical and Molecular Biomedicine (MEDBIO) (A M Borzi MD), Department of General Surgery and Medical-Surgical Specialties (Prof A Biondi PhD, M Vacante PhD), University of Catania, Catania, Italy; Department of Clinical Medicine (Prof K Soreide PhD), Department of Global Public Health and Primary Care (Prof T Bjørge PhD), University of Bergen, Bergen, Norway; Cancer Registry of Norway, Oslo, Norway (Prof T Bjørge PhD); Department of Environmental Health Science (S Gallus DSc), Department of Oncology (C Bosetti PhD), Mario Negri Institute for Pharmacological Research, Milan, Italy; Department of Biomedical Technologies (A N Briko MSc), Bauman Moscow State Technical University, Moscow, Russia; Department of Epidemiology and Evidence-Based Medicine (Prof N I Briko DSc, P D Lopukhov Cand of Sci [Med]), I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Institute for Cancer Research, Prevention and Clinical Network, Oncological Network, Prevention and Research Institute (ISPRO), Florence, Italy (G Carreras PhD); Applied Molecular Biosciences Unit (Prof F Carvalho PhD), Institute of Public Health (Prof F Carvalho PhD), REQUIMTE/LAQV (Prof E Fernandes PhD), University of Porto, Porto, Portugal; Department of Biochemistry, Biomedical Science (J J Choi PhD), Seoul National University Hospital, Seoul, South Korea; Faculty of Biology (D Chu PhD), Hanoi National University of Education, Hanoi, Vietnam; Institute for Global Health Innovations (A K Dang MD, C T Nguyen MPH), Duy Tan University, Hanoi, Vietnam; Toxoplasmosis Research Center (Prof A Daryani PhD),

Mazandaran University of Medical Sciences, Sari, Iran; Department of General Surgery (I Negoï PhD, D V Davitoiu PhD), Emergency Hospital of Bucharest (I Negoï PhD), Faculty of Dentistry, Department of Legal Medicine and Bioethics (S Hostiu PhD), Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Surgery (D V Davitoiu PhD), Clinical Emergency Hospital Sf. Pantelimon, Bucharest, Romania; School of Pharmacy (G T Demoz MPharm), Aksum University, Aksum, Ethiopia; Department of Pharmacology (D Z Wondafrash MSc), Addis Ababa University, Addis Ababa, Ethiopia (G T Demoz MPharm); Division of Cardiology (R Desai MBBS), Atlanta Veterans Affairs Medical Center, Decatur, GA, USA; Disha Foundation, Gurgaon, India (S Dey PhD); Center of Excellence in Behavioral Medicine (H P Do PhD, C L Hoang BMedSc, L H Nguyen PhD, T H Nguyen BMedSc), Center of Excellence in Public Health Nutrition (H T Do MD), Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam; Department of Microbiology (A Hasanzadeh PhD), Pharmacology and Toxicology Department (A Eftekhari PhD), Maragheh University of Medical Sciences, Maragheh, Iran; Psychiatry Department (I Filip MD), Kaiser Permanente, Fontana, CA, USA; College of Graduate Health Sciences (A Radfar MD), Department of Health Sciences (I Filip MD), A.T. Still University, Mesa, AZ, USA; Department of Public Health Medicine (F Fischer PhD), Bielefeld University, Bielefeld, Germany; Abadan School of Medical Sciences, Abadan, Iran (M Foroutan PhD); Department of Cardiovascular Medicine (M M Gad MD), Cleveland Clinic, Cleveland, OH, USA; Gillings School of Global Public Health (M M Gad MD), University of North Carolina Chapel Hill, Chapel Hill, NC, USA; Occupational and Environmental Epidemiology Section (G Gorini MD), Cancer Prevention and Research Institute, Florence, Italy; Department of Radiology and Radiological Sciences (N Hafezi-Nejad MD, S Sheikhbahaei MD), Johns Hopkins University, Baltimore, MD, USA; Gastrointestinal and Liver Disease Research Center (S Hassanipour PhD, F Joukar PhD, Prof F Mansour-Ghanaei PhD), Guilan University of Medical Sciences, Rasht, Iran (S Hassanipour PhD); Department of Epidemiology (H D Hidru MPH), Adigrat University, Adigrat, Ethiopia; Clinical Legal Medicine (S Hostiu PhD), National Institute of Legal Medicine Mina Minovici, Bucharest, Romania; Division of Information and Computing Technology (Prof M Househ PhD), Hamad Bin Khalifa University, Doha, Qatar; Qatar Foundation for Education, Science, and Community Development, Doha, Qatar (Prof M Househ PhD); Department of Community Medicine (O S Ilesanmi PhD), University of Ibadan, Ibadan, Nigeria; Department of Epidemiology (Prof M D Ilic PhD), University of Kragujevac, Kragujevac, Serbia; Research Institute for Endocrine Sciences (S N Irvani MD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Psychosis (N Jafari Balalami PhD), Babol Nushirvani University of Technology, Babol, Iran; Clinical Pharmacy Unit (T D Kassa MSc), Department of Pharmacology and Toxicology (D Z Wondafrash MSc), Mekelle University, Mekelle, Ethiopia (H G Meles MPH); Non-communicable Diseases Research Unit (Prof A P Kengne PhD), Medical Research Council South Africa, Cape Town, South Africa; Department of Medicine (Prof A P Kengne PhD), University of Cape Town, Cape Town, South Africa; Epidemiology and Biostatistics Department (E A Khan MPH), Health Services Academy, Islamabad, Pakistan; Internal Medicine and Gastroenterology Department (A Khater MD), National Hepatology and Tropical Research Institute, Cairo, Egypt; Department of Epidemiology (F Khosravi Shadmani PhD), Kermanshah University of Medical Sciences, Kermanshah, Iran; Public Health Sciences Division (J M Kocarnik PhD), Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Neurophysiology Research Center (H Komaki MD), Hamadan University of Medical Sciences, Hamadan, Iran; Brain Engineering Research Center (H Komaki MD), Institute for Research in Fundamental Sciences, Tehran, Iran; CIBERSAM (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain (A Koyanagi MD); Department of Medicine, Brigham and Women's Hospital (V Kumar MD), Harvard University, Boston, MA, USA; Clinical Medicine and Community Health Department (Prof C La Vecchia MD), Department of Nursing, A.C.S. Medical College and Hospital, Milano, Italy (D B B Tadesse CAP); Ophthalmology Department (N Manafi MD), University of Manitoba, Winnipeg, MB, Canada; Surgery Department (A Manda MD), Emergency University Hospital Bucharest, Bucharest, Romania; Division of Gastroenterology and Hepatobiliary Disease (D Mehta MD), New York Medical College, Valhalla, NY, USA; Department of Internal Medicine (V Mehta MD), SevenHills Hospital, Mumbai, India; Institute for Agricultural and Nutritional Sciences (T Meier PhD), Martin Luther University Halle-Wittenberg, Halle, Germany; Innovation Office (T Meier PhD), Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Halle, Germany; School of Pharmacy (G Mengistu MSc, M Sisay MSc), Haramaya University, Harar, Ethiopia; Department of Propedeutics of Internal Diseases & Arterial Hypertension (Prof T Miazgowski MD), Pomeranian Medical University, Szczecin, Poland; Department of Epidemiology and Biostatistics (A Mohammadian-Hafshejani PhD), Shahrekord University of Medical Sciences, Shahrekord, Iran; Department of Clinical Biochemistry (M Mohammadoo-Khorasani PhD), Tarbiat Modares University, Tehran, Iran; Health Systems and Policy Research Unit (S Mohammed PhD), Ahmadu Bello University, Zaria, Nigeria; Institute of Public Health (S Mohammed PhD), Heidelberg University, Heidelberg, Germany; Clinical Epidemiology and Public Health Research Unit (L Monasta DSc, E Traini MSc), Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; Department of Molecular Medicine (M Moossavi PhD), Birjand University of Medical Sciences, Birjand, Iran; Department of Epidemiology (R Moradzadeh PhD), Arak University of Medical Sciences, Arak, Iran; Department of Epidemiology (G Naik MPH), University of Alabama at Birmingham, Birmingham, AL, USA; Department of Pathology and Molecular Medicine (T O Olagunju MD), Department of Psychiatry and Behavioural Neurosciences (A T Olagunju MD), McMaster University, Hamilton, ON, Canada; Department of Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; Biomedical Engineering Department (Prof M Rabiee PhD), Amirkabir University of Technology, Tehran, Iran; Medichem, Barcelona, Spain (A Radfar MD); Department of Radiation Oncology (Prof G K Rath MD), All India Institute of Medical Sciences, New Delhi, India; Department of Primary Care and Public Health (Prof S Rawaf MD), WHO Collaborating Centre for Public Health Education and Training (D L Rawaf MD), Imperial College London, London, UK; University College London Hospitals, London, UK (D L Rawaf MD); Academic Public Health Department (Prof S Rawaf MD), Public Health England, London, UK; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) (Prof N Rezaei PhD), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Department of Entomology (A M Samy PhD), Faculty of Medicine (A M Saad MBCh), Ain Shams University, Cairo, Egypt; Biotechnology Research Center (A Sahebkar PhD), Neurogenic Inflammation Research Center (A Sahebkar PhD), Mashhad University of Medical Sciences, Mashhad, Iran; Department of Surgery (Prof J Sanabria MD), Marshall University, Huntington, WV, USA; Department of Nutrition and Preventive Medicine (Prof J Sanabria MD), Case Western Reserve University, Cleveland, OH, USA; Department of Public Health Sciences (M Sawhney PhD), University of North Carolina at Charlotte, Charlotte, NC, USA; Department of Medical Statistics, Epidemiology and Medical Informatics (M Sekerija PhD), University of Zagreb, Zagreb, Croatia; Division of Epidemiology and Prevention of Chronic Noncommunicable Diseases (M Sekerija PhD), Croatian Institute of Public Health, Zagreb, Croatia; Cancer Research and Development Department (Prof P Shabalkin MD), N.N. Blokhin National Medical Cancer Research Center, Moscow, Russia; independent consultant, Karachi, Pakistan (M A Shaikh MD); University School of Management and Entrepreneurship (R Sharma PhD), Delhi Technological University, New Delhi, India; Department of Hematology-Oncology (S K Siddappa Malleshappa MD), Baystate Medical Center, Springfield, MA, USA; Department of Gastrointestinal Surgery (Prof K Soreide PhD), Stavanger University Hospital, Stavanger, Norway; Research Development Department (S Soshnikov PhD), Central Research Institute of Cytology and Genetics (E Varavikova PhD), Federal Research Institute for Health Organization and Informatics of the Ministry of Health (FRIHOI), Moscow, Russia (Prof V I Starodubov DSc); Department of Medicine (Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; Carlos III Health Institute

(Prof R Tabarés-Seisdedos PhD), Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain; Department of Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, Vietnam; Department of Molecular Medicine and Pathology (K B Tran MD), University of Auckland, Auckland, New Zealand; Department of Clinical Hematology and Toxicology (K B Tran MD), Military Medical University, Hanoi, Vietnam; Gomal Center of Biochemistry and Biotechnology (I Ullah PhD), Gomal University, Dera Ismail Khan, Pakistan; TB Culture Laboratory (I Ullah PhD), Mufti Mehmood Memorial Teaching Hospital, Dera Ismail Khan, Pakistan; Baqiyatallah University of Medical Sciences, Tehran, Iran (A Vahedian-Azimi PhD); Competence Center of Mortality-Follow-Up, German National Cohort (R Westerman DSc), Federal Institute for Population Research, Wiesbaden, Germany; Department of Psychopharmacology (N Yonemoto MPH), National Center of Neurology and Psychiatry, Tokyo, Japan; Epidemiology and Cancer Registry Sector (Prof V Zadnik PhD), Institute of Oncology Ljubljana, Ljubljana, Slovenia; and Department of Preventive Medicine (Z Zhang PhD), Wuhan University, Wuhan, China.

#### Contributors

AP, SGS, SS, GR, CF, MN, and CJLM prepared the first draft. RM, MM, RS, MK, CF, MN, and CJLM provided overall guidance. RM, SGS, AP, CF, MN, and CJLM managed the project. SGS, SS, and CF analysed data. RM, SGS, AK, RS, SS, CF, MN, and CJLM finalised the manuscript on the basis of comments from other authors and reviewer feedback. All other authors provided data, developed models, reviewed results, provided guidance on methods, or reviewed and contributed to the manuscript.

#### Declaration of interests

SLJ reports grants from Sanofi Pasteur, outside the submitted work. All other authors declare no competing interests.

#### Acknowledgments

This study was supported by the Bill & Melinda Gates Foundation. AB is supported by the Public Health Agency of Canada. FC and EF acknowledge UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES) through Portuguese national funds. TM acknowledges institutional support from the Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena-Halle-Leipzig. AMS acknowledges support by a fellowship from the Egyptian Fulbright Mission Program (EFMP). RT-S acknowledges support in part by grant number PROMETEOII/2015/021 from Generalitat Valenciana and the national grant PI17/00719 from ISCIII-FEDER.

Editorial note: The *Lancet* Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

#### References

- Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. *JAMA Oncol* 2018; **4**: 1553–68.
- Wong MC, Jiang JY, Liang M, Fang Y, Yeung MS, Sung JJ. Global temporal patterns of pancreatic cancer and association with socioeconomic development. *Sci Rep* 2017; **7**: 3165.
- McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* 2018; **24**: 4846–61.
- Capasso M, Franceschi M, Rodriguez-Castro KI, et al. Epidemiology and risk factors of pancreatic cancer. *Acta Biomed* 2018; **89**: 141–46.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789–858.
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1859–922.
- GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1736–88.
- GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1923–94.
- GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1995–2051.
- GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2019; **393**: 1958–72.
- Foreman KJ, Lozano R, Lopez AD, Murray CJL. Modeling causes of death: an integrated approach using CODEM. *Popul Health Metr* 2012; **10**: 1.
- Neal RD, Din NU, Hamilton W, et al. Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database. *Br J Cancer* 2014; **110**: 584–92.
- Howlander N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975–2015. National Cancer Institute. September, 2018. [https://seer.cancer.gov/csr/1975\\_2015/](https://seer.cancer.gov/csr/1975_2015/) (accessed April 30, 2018).
- Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. *Br J Cancer* 2011; **105** (suppl 2): S77–81.
- Gowing LR, Ali RL, Allsop S, et al. Global statistics on addictive behaviours: 2014 status report. *Addiction* 2015; **110**: 904–19.
- Avgerinos DV, Bjornsson J. Malignant neoplasms: discordance between clinical diagnoses and autopsy findings in 3,118 cases. *APMIS* 2001; **109**: 774–80.
- Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. *Bull World Health Organ* 2005; **83**: 171–77.
- Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Arch Intern Med* 2010; **170**: 791–802.
- Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet* 2016; **387**: 1377–96.
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016; **387**: 1513–30.
- GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet* 2017; **389**: 1885–906.
- Ilic M, Ilic I. Epidemiology of pancreatic cancer. *World J Gastroenterol* 2016; **22**: 9694–705.
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; **74**: 2913–21.
- Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. *Acta Oncol* 2016; **55**: 1158–60.
- Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *Lancet* 2018; **392**: 2052–90.
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin* 2010; **60**: 277–300.
- Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. *Int J Epidemiol* 2014; **44**: 186–98.
- Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). *Ann Oncol* 2012; **23**: 1880–88.

- 29 IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC, 2004: 1–1452.
- 30 Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. *Ann Surg Oncol* 2014; **21**: 2453–62.
- 31 Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. *Diabetes* 2017; **66**: 1103–10.
- 32 Bosetti C, Rosato V, Li D, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. *Ann Oncol* 2014; **25**: 2065–72.
- 33 Rosato V, Polesel J, Bosetti C, Serraino D, Negri E, La Vecchia C. Population attributable risk for pancreatic cancer in Northern Italy. *Pancreas* 2015; **44**: 216–20.
- 34 Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. *Cancer Causes Control* 2011; **22**: 189–97.
- 35 Jiao L, Berrington de Gonzalez A, Hartge P, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. *Cancer Causes Control* 2010; **21**: 1305–14.
- 36 Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. *Lancet* 2011; **377**: 557–67.
- 37 Moossavi S, Mohamadnejad M, Pourshams A, et al. Opium use and risk of pancreatic cancer: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev* 2018; **27**: 268–73.
- 38 Shakeri R, Kamangar F, Mohamadnejad M, et al. Opium use, cigarette smoking, and alcohol consumption in relation to pancreatic cancer. *Medicine* 2016; **95**: e3922.